INTRODUCTION: Immunotherapy effectively treats advanced renal cell carcinoma in only a limited number of patients. However, the predicted prognosis for each patient in relation to immune status and response to immunotherapy remains problematic. We analyzed tumor-infiltrating lymphocyte (TIL) subsets to determine whether these correlated with the prognoses for the patients and the response to alpha-interferon therapy. MATERIALS AND METHODS: TIL subsets from resected specimens of 79 patients were analyzed by two-color flow cytometry and then compared with the patients' long-term clinical courses and responses to interferon therapy. RESULTS: In patients with stages III and IV, an increased infiltration of CD4+ cells and decreased CD8+ cells constituted a fair prognostic factor. In 17 patients with metastatic lesions, 8 of 10 patients who had disease progression after interferon therapy showed an increase in CD8+ cells above 25%, whereas 2 responders and 5 patients who had stable disease showed infiltration of CD8+ cells below 25%. CONCLUSIONS: The TIL subset is a prognostic factor for advanced renal cell carcinoma, and its analysis provides a method to predict the susceptibility to interferon therapy. Copyright 2002 S. Karger AG, Basel
INTRODUCTION: Immunotherapy effectively treats advanced renal cell carcinoma in only a limited number of patients. However, the predicted prognosis for each patient in relation to immune status and response to immunotherapy remains problematic. We analyzed tumor-infiltrating lymphocyte (TIL) subsets to determine whether these correlated with the prognoses for the patients and the response to alpha-interferon therapy. MATERIALS AND METHODS: TIL subsets from resected specimens of 79 patients were analyzed by two-color flow cytometry and then compared with the patients' long-term clinical courses and responses to interferon therapy. RESULTS: In patients with stages III and IV, an increased infiltration of CD4+ cells and decreased CD8+ cells constituted a fair prognostic factor. In 17 patients with metastatic lesions, 8 of 10 patients who had disease progression after interferon therapy showed an increase in CD8+ cells above 25%, whereas 2 responders and 5 patients who had stable disease showed infiltration of CD8+ cells below 25%. CONCLUSIONS: The TIL subset is a prognostic factor for advanced renal cell carcinoma, and its analysis provides a method to predict the susceptibility to interferon therapy. Copyright 2002 S. Karger AG, Basel
Authors: Kyu Seo Kim; Rishi R Sekar; Dattatraya Patil; Michelle A Dimarco; Haydn T Kissick; Mehmet A Bilen; Adeboye O Osunkoya; Viraj A Master Journal: Oncoimmunology Date: 2018-01-10 Impact factor: 8.110
Authors: K Hotta; M Sho; K Fujimoto; K Shimada; I Yamato; S Anai; N Konishi; Y Hirao; K Nonomura; Y Nakajima Journal: Br J Cancer Date: 2011-09-20 Impact factor: 7.640
Authors: Yasin Şenbabaoğlu; Ron S Gejman; Andrew G Winer; Ming Liu; Eliezer M Van Allen; Guillermo de Velasco; Diana Miao; Irina Ostrovnaya; Esther Drill; Augustin Luna; Nils Weinhold; William Lee; Brandon J Manley; Danny N Khalil; Samuel D Kaffenberger; Yingbei Chen; Ludmila Danilova; Martin H Voss; Jonathan A Coleman; Paul Russo; Victor E Reuter; Timothy A Chan; Emily H Cheng; David A Scheinberg; Ming O Li; Toni K Choueiri; James J Hsieh; Chris Sander; A Ari Hakimi Journal: Genome Biol Date: 2016-11-17 Impact factor: 13.583
Authors: Veronika Kremer; Maarten A Ligtenberg; Rosa Zendehdel; Christina Seitz; Annet Duivenvoorden; Erik Wennerberg; Eugenia Colón; Ann-Helén Scherman-Plogell; Andreas Lundqvist Journal: J Immunother Cancer Date: 2017-09-19 Impact factor: 13.751